Piperidine-Induced DNA Strand Cleavage at 5-Methylcytosine
FULL PAPER
À
À
acetate. The organic layer was washed with brine, dried over Na2SO4, fil-
tered, and concentrated. The crude product was purified by column chro-
matography (SiO2, 30% ethyl acetate/hexane) to give 2 (229 mg 72%) as
a colorless oil: 1H NMR (CDCl3, 400 MHz): d=9.26 (s, 1H; azole), 8.22
(t, 1H, J=6.6 Hz; C1’ H), 5.27 (d, 1H, J=4.3 Hz; C3’ OH), 5.11 (t, 1H,
À
À
À
J=5.1 Hz; C5’ OH) 4.28–4.24 (1H; C4’ H), 3.81 (1H; C3’ H), 3.67–3.55
(2H; C5’ H), 2.31–2.06 ppm (2H; C2’ H); 13C NMR ([D6]DMSO,
100 MHz): d=178.1, 159.2, 147.4, 138.9, 136.7, 132.5, 129.3, 128.3, 109.7,
104.8, 87.7, 84.9, 70.0, 53.5, 20.5 ppm; FABMS (matrix: glycerol): m/e:
349 [(M+H)+]; HRMS: calcd for C17H17D3N3O5: 349.1591; found:
349.1591.
À
À
À
À
(s, 1H; azole), 8.08 (s, 1H; C6 H), 6.27 (t, 1H, J=6.2 Hz; C1’ H), 4.39–
À
À
À
4.35 (1H; C4’ H), 4.04 (1H; C3’ H), 3.94 (dd, 1H, J=11.6, 2.6 Hz; C5’
À
H), 3.78 (dd, 1H, J=11.6, 2.6 Hz; C5’ H), 2.62 (ddd, 1H, J=13.5, 6.2,
À
À
3.7 Hz; C2’ H), 2.09–2.02 (1H; C2’ H), 0.89 (s, 9H; TBS), 0.88 (s, 9H;
TBS), 0.09 (d, 6H, J=5.1 Hz; TBS), 0.06 ppm (d, 6H, J=4.9 Hz; TBS);
13C NMR (CDCl3, 100 MHz): d=158.1, 153.9, 153.4, 146.6, 145.0, 105.1,
88.8, 87.8, 71.6, 62.6, 42.6, 25.9, 25.7, 18.4, 18.0, À4.5, À4.9, À5.3,
À5.4 ppm; FABMS (matrix: 3-nitrobenzyl alcohol): m/e: 525 [(M+H)+];
HRMS: calcd for C24H41D3N5O4Si2: 525.3120; found: 525.3132.
5’-Dimethoxytrityl-N-benzoyl-5-([D3]methyl)-2’-deoxycytidine (6): 4,4’-
Dimethoxytritylchroride (420 mg, 1.24 mmol) was added to a solution of
5 (300 mg, 0.86 mmol) in anhydrous pyridine and the mixture was stirred
at room temperature for 2.5 h. The reaction was quenched with methanol
(1 mL) and the solvent was evaporated under reduced pressure. The
crude product was purified by column chromatography (SiO2, 0–5%
methanol/dichloromethane with 1% triethylamine) to give 6 (547 mg,
92%) as a foam: 1H NMR ([D6]DMSO, 400 MHz): d=8.17 (d, 2H, J=
7.1 Hz; Bz), 7.79 (s, 1H; C6 H), 7.60–7.22 (13H; DMTr, Bz), 6.90 (dd,
4H J=8.8, 2.0 Hz; DMTr), 6.20 (t, 1H, J=6.5 Hz; C1’ H), 5.36 (d, 1H,
J=4.6 Hz; C3’ OH), 4.34 (1H; C4’ H), 3.94–3.93 (1H; C3’ H), 3.72 (s,
6H; OCH3), 3.31–3.23 (2H; C5’ H), 2.32–2.24 ppm (2H; C2’ H);
13C NMR ([D6]DMSO, 100 MHz): d=178.1, 161.9, 158.9, 158.6, 158.1,
149.6, 147.4, 144.7, 138.3, 137.3, 136.6, 135.4, 135.2, 132.5, 129.7, 129.3,
128.9, 128.3, 128.2, 127.9, 127.7, 126.8, 125.3, 123.9, 113.2, 110.0, 85.9,
84.9, 70.2, 63.5, 55.0, 21.0 ppm; FABMS (matrix: 3-nitrobenzyl alcohol):
m/e: 651 [(M+H)+]; HRMS: calcd for C38H35D3N3O7: 651.2898; found:
651.2888.
3’,5’-O-Bis(tert-butyldimethylsilyl)-5-([D3]methyl)-2’-deoxycytidine (3):
25% Ammonium deuteroxide (10 mL) was added to a solution of 2
(732 mg, 1.4 mmol) in acetonitrile (20 mL) and the mixture was stirred at
room temperature for 4 h. The reaction mixture was concentrated in
vacuo, then diluted with water and extracted with ethyl acetate. The or-
ganic layer was washed with brine, dried over Na2SO4, filtered, and con-
centrated. The crude product was purified by column chromatography
À
À
À
À
À
À
À
(SiO2, 33% acetone/chloroform) to give 3 (730 mg, quant.) as a colorless
1
À
oil: H NMR (CDCl3, 400 MHz): d=7.57 (s, 1H; C6 H), 6.30 (t, 1H, J=
À
À
À
À
6.5 Hz; C1’ H), 4.35–4.32 (1H; C4’ H), 3.92–3.84 (2H; C3’ H, C5’ H),
3.74 (dd, 1H, J=11.3, 2.6 Hz; C5’ H), 2.36 (1H; C2’ H), 1.95 (dd, 1H,
À
À
À
J=13.4, 6.6 Hz; C2’ H), 0.88 (18H; TBS), 0.06 ppm (12H; TBS);
13C NMR (CDCl3, 100 MHz): d=165.2, 155.6, 138.4, 101.2, 87.7, 85.9,
71.8, 62.7, 42.2, 29.3, 25.9, 25.7, 18.4, 18.0, À4.6, À4.9, À5.4 ppm; FABMS
(matrix: 3-nitrobenzyl alcohol): m/e: 473 [(M+H)+]; HRMS: calcd for
C22H41D3N3O4Si2: 473.3059; found: 473.3045.
3’-(N,N-Diisopropylmethylphosphonamidite)-5’-dimethoxytrityl-N-benzo-
yl-5-([D3]methyl)-2’-deoxycytidine (7): Compound 6 was coevaporated
twice with anhydrous acetonitrile (1 mL). N,N-Diisopropylmethyl phos-
phonamidic chloride (16 mL, 0.082 mmol) was added to a solution of 6
(50 mg, 0.077 mmol) and diisopropylethylamine (39 mL, 0.23 mmol) in an-
hydrous acetonitrile (0.75 mL) and the mixture was stirred at room tem-
perature for 1.5 h. The reaction mixture was filtered and then placed on
a DNA synthesizer.
5-[D3]Methyl-2’-deoxycytidine ([D3]dmC): Acetic acid (32.5 mL) and tet-
rabutylammonium fluoride (1.2 mL, 1.2 mmol) were added to a solution
of 3 (179 mg, 0.38 mmol) in anhydrous tetrahydrofuran (3.8 mL) and the
mixture was stirred at room temperature for 7 h. The reaction mixture
was concentrated. The crude product was roughly purified by column
chromatography (SiO2, 20% methanol/chloroform with 2% triethyl-
amine) and then purified by reversed-phase HPLC (7% methanol/water)
to give [D3]dmC (58 mg, 63%) as a white solid: 1H NMR (CD3OD,
Synthesis of ODNs containing a C5-deuterated 5-methylcytosine base:
ODNs containing 5-[D3]methyl-2’-deoxycytidine were synthesized on an
Applied Biosystems Model 3400 DNA/RNA synthesizer by using stan-
dard b-cyanoethylphosphramidite chemistry. Synthesized ODNs were pu-
rified by reversed-phase HPLC on an Inertsil ODS-3 column (10ꢁ
250 mm, elution with a solvent mixture of 0.1m triethylammonium ace-
tate (TEAA) at pH 7.0, linear gradient over 60 min from 0% to 30%
acetonitrile at a flow rate of 3.0 mLminÀ1). The purity and concentration
of the modified ODN was determined by complete digestion with AP,
P1, and phosphodiesterase I. The synthesized ODN ([D3]mC) was identi-
fied by MALDI-TOF mass spectrometry ([MÀH]À; calcd: 5583.67;
found: 5585.5).
À
À
400 MHz): d=7.76 (s, 1H; C6 H), 6.16 (t, 1H, J=6.5 Hz; C1’ H), 4.30–
À
À
À
4.26 (1H; C4’ H), 3.82 (1H; C3’ H), 3.74–3.62 (2H; C5’ H), 2.23 (ddd,
1H, J=13.5, 6.2, 3.7 Hz; C2’ H), 2.07–2.01 ppm (1H; C2’ H); 13C NMR
(CD3OD, 100 MHz): d=167.1, 158.0, 140.2, 104.2, 88.8, 87.3, 71.9, 62.7,
42.0, 30.7 ppm; FABMS (matrix: glycerol): m/e: 245 [(M+H)+]; HRMS:
calcd for C10H13D3N3O4: 245.1329; found: 245.1329.
À
À
3’,5’-O-Bis(tert-butyldimethylsilyl)-N-benzoyl-5-([D3]methyl)-2’-deoxycy-
tidine (4): Benzoyl chloride (40 mL, 0.33 mmol) was added to a solution
Synthesis of ODNs possessing 9,10-anthraquinone (AQ) sensitizer:
of
3
(100 mg, 0.21 mmol) and 4-dimethylaminopyridine (55 mg,
0.45 mmol) in anhydrous dichloromethane (9.5 mL). The reaction was
stirred at room temperature overnight. The reaction was quenched with
methanol (1 mL) and concentrated under reduced pressure. The crude
product was purified by column chromatography (SiO2, 20% ethyl ace-
Synthesis of ODN 1ACTHNGUTERNNU(G AQ1): 10 mm AQ-NHS in acetonitrile solution con-
taining 20 vol% dimethylformamide (45 mL) and saturated NaHCO3
(30 mL) were added to a 1.2 mm solution (total volume: 75 mL) of ODNs
possessing an aminohexyl linker internally and incubated at 378C over-
night. The reaction mixture was first subjected to gel filtration by using
MicroBio-spin 6 columns (BioRad) and then purified by reversed-phase
HPLC with a 0–30% linear gradient (over 30 min) of acetonitrile/0.1m
TEAA buffer solution at pH 7.0. The purity and concentration of the
AQ-modified ODN were determined by complete digestion with AP, P1,
1
tate/hexane) to give 4 (114 mg, 94%) as a white foam: H NMR (CDCl3,
À
400 MHz): d=8.30 (2H; Bz), 7.67 (s, 1H; C6 H), 7.49 (3H; Bz), 6.32
À
À
À
(dd, 1H, J=7.6, 6.0 Hz; C1’ H), 4.39 (1H; C4’ H), 3.96 (1H; C3’ H),
À
3.88 (dd, 1H, J=11.4, 2.4 Hz; C5’ H), 3.76 (dd, 1H, J=11.4, 2.4 Hz;
À
À
À
C5’ H), 2.34–2.29 (1H; C2’ H), 2.01 (1H; C2’ H), 0.91 (18H; TBS),
0.11 ppm (12H; TBS); 13C NMR (CDCl3, 100 MHz): d=179.6, 159.8,
147.9, 137.3, 136.8, 132.3, 129.9, 128.1, 111.5, 88.1, 85.5, 72.3, 63.0, 41.7,
27.6, 25.9, 25.7, 18.4, 18.0, À4.6, À4.8, À5.4 ppm; FABMS (matrix: 3-ni-
trobenzyl alcohol): m/e: 577 [(M+H)+]; HRMS: calcd for
C29H45D3N3O5Si2: 577.3321; found: 577.3310.
and phosphodiesterase I. The synthesized ODN 1ACHTNUTGRNEUNG(AQ1) was identified by
MALDI-TOF mass spectrometry ([MÀH]À; calcd: 5546.68; found:
5546.84).
Synthesis of ODN 1ACTHNUTRGNEUNG(AQ2): Saturated 2-(3-bromopropionamido)anthra-
quinone (approximately 5 mm) in ethanol solution (250 mL) and saturated
NaHCO3 (30 mL) were added to a 0.6 mm solution (total volume: 480 mL)
of ODNs possessing an aminohexyl linker internally and incubated at
608C for 20 h. The reaction mixture was purified by reversed-phase
N-Benzoyl-5-([D3]methyl)-2’-deoxycytidine (5): Triethylamine trihydro-
genfluoride (43 mL, 0.26 mmol) was added to a solution of 4 (50 mg,
0.087 mmol) in anhydrous tetrahydrofuran (0.9 mL). The reaction mix-
ture was stirred at room temperature overnight. The solvent was re-
moved under reduced pressure. The crude product was purified by
column chromatography (SiO2, 0–10% methanol/chloroform) to give 5
(30 mg, quant.) as a white foam: 1H NMR ([D6]DMSO, 400 MHz): d=
HPLC. The synthesized ODN 1ACHTNUTRGNENU(G AQ2) was identified by ESI-TOF mass
spectrometry ([MÀ4H]4À; calcd: 1392.4; found: 1392.5).
Photosensitized oxidation of 5-methyl-2’-deoxycytidine by anthraquinone
2-sulfonate: A solution of dmC (200 mm) in 2 mm sodium cacodylate
buffer (pH 7.0) containing 20 mm NaCl was added to an aqueous solution
À
8.19 (d, 2H, J=7.1 Hz; Bz), 8.06 (s, 1H; C6 H), 7.64–7.47 (3H; Bz), 6.16
Chem. Eur. J. 2011, 17, 2225 – 2235
ꢀ 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2233